Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights

Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial

Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock

Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

Rocket receives $150m credit facility to advance cardiovascular portfolio

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility